Chlamydia PMP proteins, gene sequences and uses thereof

Details Chlamydia PMP proteins, gene sequences and uses thereof Chlamydia PMP proteins, gene sequences and uses thereof

2001-09-28

2010-06-08

Minnifield, N. M. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S184100, C424S234100, C530S350000

Reexamination Certificate

active

07731980

ABSTRACT:
The invention discloses theChlamydiaPMPE and PMPI polypeptide, polypeptides derived therefrp, (PMP-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the PMP polypeptides and PMP-derived polypeptides and T-cells specific for PMP polypeptides and PMP-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising PMP polypeptides or PMP-derived polypeptides or antibodies thereto. The invention additionally discloses methods of inducing in animals an immune response toChlamydiacells,Chlamydiaelementary bodies, and/or cells expressing Chlamydial proteins, e.g., cell infected withChlamydia.

REFERENCES:
patent: 4427782 (1984-01-01), Caldwell et al.
patent: 5071962 (1991-12-01), Morrison et al.
patent: 5516638 (1996-05-01), Urnovitz et al.
patent: 5679547 (1997-10-01), Krivan et al.
patent: 5721115 (1998-02-01), Krivan et al.
patent: 5725863 (1998-03-01), Daniels et al.
patent: 5770714 (1998-06-01), Agabian et al.
patent: 5869608 (1999-02-01), Caldwell et al.
patent: 5965141 (1999-10-01), Briles et al.
patent: 5976544 (1999-11-01), Charles et al.
patent: 6166177 (2000-12-01), Probst et al.
patent: 6432916 (2002-08-01), Probst et al.
patent: 6447779 (2002-09-01), Probst et al.
patent: 6448234 (2002-09-01), Fling et al.
patent: 6559294 (2003-05-01), Griffais et al.
patent: 6565856 (2003-05-01), Skeiky et al.
patent: 6642023 (2003-11-01), Jackson et al.
patent: 6887843 (2005-05-01), Jackson et al.
patent: 2002/0061848 (2002-05-01), Bhatia et al.
patent: 2004/0067524 (2004-04-01), Jackson et al.
patent: 2004/0137005 (2004-07-01), Jackson et al.
patent: 2005/0048557 (2005-03-01), Jackson et al.
patent: WO 99/27105 (1993-06-01), None
patent: WO 96/40893 (1996-12-01), None
patent: WO 99/28474 (1999-06-01), None
patent: WO 99/28475 (1999-06-01), None
patent: WO 00/27994 (2000-05-01), None
patent: WO 00/34483 (2000-06-01), None
patent: WO 00/34488 (2000-06-01), None
patent: WO 01/40474 (2001-06-01), None
patent: WO 02/08267 (2002-01-01), None
patent: WO 02/062380 (2002-08-01), None
Stephens et al (Science vol. 282, Oct. 23, 1998, p. 754-759.
NCBI sequence listing for pmpI, created 1998, locus, AAC68472.
Longbottom et al (Infection and Immunity, Apr. 1998, p. 1317-1324).
U.S. Appl. No. 08/942,596, filed Oct. 2, 1997, Jackson and Pace.
U.S. Appl. No. 09/542,520, filed Apr. 3, 2000, Jackson and Pace.
U.S. Appl. No. 09/612,402, filed Jul. 6, 2000, Jackson and Pace.
Caldwell, et al, 1981, “Purification and Partial Characterization of the Major Outer Membrane Protein ofChlamydia trachomatis”, Infect.Immun., 31: 1161-1176.
Cerrone et al., 1991, “Cloning and Sequence of the Gene for Heat Shock Protein 60 fromChlamydia trachomatisand Immunological Reactivity of the Protein”, Infect. Immun., 59(1): 79-90.
Chen et al., 1994 “Trachoma and LGV biovars ofChlammydia trachomatisshare the same glycosaminoglycan-dependent mechanism for infection of eukaryotic cells”, Molec. Microbiol. 11(3): 501-507.
http://chlamydia-www.berkeley.edu.
Murdin, et al., 1993, “A Poliovirus Hybrid Expressing a Neutralization Epitope from the Major Outer Membrane Protein ofChlamydia trachomatisis highly immunogenic”, Infect.Immun., 61: 4406-4414.
Murdin et al., 1995, “Poliovirus Hybrids Expressing Neutralization Epitopes from Variable Domains I and IV of the Major Outer Membrane Protein ofChlamydia trachomatisElicit Broadly Cross-ReactiveC. Trachomatis-neutralizing antibodies”, Infect. Immun., 63(3): 1116-1121.
Rostand, et al., 1997, “Microbial Adherence to and Invasion through Proteoglycans”, Infect. Immun. 65(1): 1-8.
Stephens, Richard S., 1994, “Molecular mimicry andChlamydia trachomatisinfection of eukaryotic cells”, Trends in Microbiol. 2(3): 99-101.
Swanson, et al., 1990, “Identification of Lectin-Binding Proteins inChlamydiaSpecies”, Infect. Immun. 58(2): 502-507.
Wagar et al., 1988, “Developmental-Form-Specific DNA-Binding Proteins inChlamydiaspp.”, Infect. Immun. 56(7): 1678-1684.
Zhang et al., 1992, “Mechanism ofC. trachomatisAttachment to Eukaryotic Host Cells”, Cell 69: 861-869.
Bannatine et al., 1999, “Use of a primate model system to identifyChlamydia trachomatisprotein antigens recognized uniquely in the context of infection”, Microbiology 145:2077-2085.
Pal et al., 2000, “Immunogenic and protective ability of the two developmental forms ofChlamydiaein a mouse model of infertility”, Vaccine 18: 752-61.
Peterson et al., 1999, “Intranasal immunization withChlamydia trachomatis, serovar E, protects from a subsequent vaginal challenge with the homologous serovar”, Vaccine 17: 2901-2907.
Stephens et al., 2000, “ChlamydialGenomics and Vaccine Antigen Discovery”, J. of Infectious Diseases 181: S521-S523.
Birkelund et al., Infection & Immunity, 56(3):654-59, Mar. (1988).
Buenida et al., FEMS Microbiol. Lttrs., May 1, 150(1):113-119 (1997).
Li et al., PNAS 77(6):3211-14 (1980).
DeSa et al., Infection & Immunity, Dec., 63(12):4912-16 (1995).
Sexton et al., J. of Immunol., 152(4):1861-72 (1994).
Su et al., PNAS 93:11143-48 (1986).
Herring et al., FEMS Microbiol Letts. 65:153-158 (1989).
Tan et al., Infect Immun. 58(9) 3101-3108 (1990).
Zhang et al., Nucleic Acids Res. 18(4):1061 (1990).
Stephens et al., J. Bacteriol 168:1277-82 (1986).
Deslauriers et al., Infection & Immunity, 64(2):434-440 Feb. (1996).
Carlson et al., Infection & Immunity, 65(6):2080-2087 Jun. (1997).
Nilsson et al., J of Clin. Invest. 101(12):2640-2649, Jun. (1998).
Stephens et al. Science 282:754-759 (1998).
Murdin et al, Infection and Immunity, Oct. 1993, p. 4406-4414.
Sequence Alignment #1 (Griffais et al.).
Sequence Alignment #2 (Probst et al.).
Longbottom et al. FEMS 165:111 (1998).
Gen Bank Accession No. Acc No. E71460.
Creighton, T.E., ed.,Protein Structure: A Practical Approach, Oxford University Press, New York, NY, pp. 184-186 (1989).
Creighton, T.E., ed.,Protein: Structure and Molecular Properties, W.H. Freeman & Co., New York, NY, pp. 314-315 (1984).
Fox, J.L., AIDS Product Development Follows its Own Rules,Biotechnology. 12:1329-1331, Nature Publishing Co. (1994).
Gu, X.X., et al., “Synthesis and Characterization of Lipooligosaccharide-based Conjugates as Vaccine Candidates forMoraxella(Branhamella)catarrhalis,” Infect. Immun. 66:1891-1897, American Society for Microbiology (1998).
Kyd, J., et al., “Investigation of Mucosal Immunisation in Pulmonary Clearance ofMoraxella(Branhamella)catarrhalis,” Vaccine 18:398-406, Elsevier Science (Oct. 1999).
Nosoh, Y. and Sekiguchi, T., eds.,Protein Stability and Stabilization through Protein Engineering, Prentice Hall Professional Technical Reference, East Rutherford, NJ, pp. 197 (1991).
Samukawa, T., et al., “Immune Response to Surface Protein A ofStreptococcus pneumoniaeand to High-Molecular-Weight Outer Membrane Protein A ofMoraxella catarrhalisin Children with Acute Otitis Media,”J. Infect. Dis. 181:1842-1845, University of Chicago Press (May 2000).
Schmitt, J., et al., “Affinity Purification of Histidine-Tagged Proteins,”Mol. Biol. Rep. 18:223-230, Reidel (1993).
Su, H., et al., “Identification and Characterization of T Helper Cell Epitopes of the Major Outer Membrane Protein ofChlamydia trachomatis,” J. Exp. Med. 172:203-212, Rockefeller University Press (1990).
Co-pending and commonly-owned U.S. Appl. No. 11/781,199, inventor Jackson, W. James, filed Jul. 20, 2007 (Not Published).
Co-pending and commonly-owned U.S. Appl. No. 11/781,203, inventor Jackson, W. James, filed Jul. 20, 2007 (Not Published).
Co-pending and commonly-owned U.S. Appl. No. 08/942,596, inventors Jackson, W. James, et al., filed Oct. 2, 1996 (Not Published).
Christiansen, G., et al., “Potential Relevance ofChlamydia pneumoniaeSurface Proteins to an Effective Vaccine,”J. Infect. Dis. 181(Suppl. 3

Affiliated with

Also associated with

Rating

Chlamydia PMP proteins, gene sequences and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chlamydia PMP proteins, gene sequences and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chlamydia PMP proteins, gene sequences and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4218621